Aug. 15, 2014
Primary effusion lymphoma (PEL) is an aggressive type of non-Hodgkin lymphoma typically associated with human herpesvirus 8 infection in immunocompromised individuals. PEL is an incurable orphan disease and has extremely poor prognosis with median survival of several months. The current standard of care for PEL is using cytotoxic chemotherapeutic agents, which increases the risk of treatment-related mortality. Given the poor prognosis and limited treatment options of PEL, there is clearly an unmet medical need to be addressed.
USC researchers have found that a combination of two types of drugs, one of which is FDA approved and the other in clinical development, yielded promising results in treating PEL. This drug combination works on molecular and cellular levels by targeting PEL cells specifically through targeting a molecular feature of PEL. This combination also successfully increased the survival of PEL xenograft mice. Moreover, these two types of drugs are synergistic. Different members from each group were tested in such combination and proved to be successful.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
non-hodgkin lymphoma typically
incurable orphan disease
cytotoxic chemotherapeutic agents
limited treatment options
yielded promising results
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium